Seattle-based startup Curi Bio landed $10 million in Series A funding for its stem cell-focused drug-exploration platforms.
This investment comes months after the company announced a $6 million funding round led by Dynamk Capital.
WHAT IT DOES
Curi Bio developed a platform called Mantrarry, which is able to help scientists “generate and analyze 3D engineered human muscle tissues.” The company's...
